Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | MMP8 | P22894 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perflenapent SCHEMBL7648533 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL984715 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL3743142 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1924377 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| Perflexane SCHEMBL3671912 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1707474 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| Perflexane SCHEMBL7507426 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1779065 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| Perflexane SCHEMBL20769778 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| Perflenapent SCHEMBL33962 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 607 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144875-A1 | COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS | ADS THERAPEUTICS LLC (US) | 2026-05-28 | — | — | US | claimed |
| CN-122075746-A | Microsphere composition, preparation method thereof and application thereof in preparation of contrast agent and medicine | — | 2026-05-26 | — | — | CN | claimed |
| US-20260130896-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2026-05-14 | — | — | US | claimed |
| US-20260124305-A1 | TOPICAL OPHTHALMOLOGICAL COMPOSITIONS | ADS THERAPEUTICS LLC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4717278-A1 | NANOVECTORS FOR MAGNETIC RESONANCE IMAGING | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2026-04-01 | — | — | EP | claimed |
| US-20250375539-A1 | COMPOSITIONS OF DISPERSED SYSTEMS FOR BIOMEDICAL APPLICATIONS, PROCESS FOR THEIR PREPARATION AND USES THEREOF | SUPERBRANCHE (FR) | 2025-12-11 | — | — | US | claimed |
| US-20250345287-A1 | COMPOSITION COMPRISING A MIXTURE OF AT LEAST ONE OIL AND ONE OR MORE SEMIFLUORINATED ALKANES, A USE OF THE COMPOSITION FOR TREATING A DISEASE AS WELL AS A METHOD OF PRODUCING THE COMPOSITION AND CORRESPONDING KITS | FLUORON GMBH (DE) | 2025-11-13 | — | — | US | claimed |
| EP-4647066-A1 | A COMPOSITION COMPRISING A MIXTURE OF AT LEAST ONE OIL AND ONE OR MORE SEMIFLUORINATED ALKANES, A USE OF THE COMPOSITION FOR TREATING A DISEASE AS WELL AS A METHOD OF PRODUCING THE COMPOSITION AND CORRESPONDING KITS | Fluoron GmbH (DE) | 2025-11-12 | — | — | EP | claimed |
| US-20250339598-A1 | EXTRACORPOREAL OXYGENATION DEVICE | BOUNDLESS SCIENCE INCORPORATED (US) | 2025-11-06 | — | — | US | claimed |
| EP-4637775-A1 | COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS | ADS Therapeutics LLC (US) | 2025-10-29 | — | — | EP | claimed |
| EP-1870398-B1 | One-pot catalytic process for the synthesis of isocyanates | REPSOL YPF SA (ES) | 2008-12-17 | — | — | EP | claimed |
| US-7423171-B2 | One-step catalytic process for the synthesis of isocyanates | REPSOL YPF, S.A. (ES) | 2008-09-09 | — | — | US | claimed |
| EP-1933393-A1 | Method of manufacturing a substrate for an electronic device | Samsung SDI Co., Ltd. (KR) | 2008-06-18 | — | — | EP | claimed |
| EP-1870398-A1 | One-pot catalytic process for the synthesis of isocyanates | REPSOL YPF S.A. (ES) | 2007-12-26 | — | — | EP | claimed |
| US-20070293696-A1 | ONE-STEP CATALYTIC PROCESS FOR THE SYNTHESIS OF ISOCYANATES | REPSOL-YPF,S.A. (ES) | 2007-12-20 | — | — | US | claimed |
| US-20050176140-A1 | Method and apparatus for cell culture using a two liquid phase bioreactor | BENEDICT DANIEL J (US) | 2005-08-11 | — | — | US | claimed |
| EP-0612240-A4 | METHOD FOR EXTENDING THE VASCULAR DWELL-TIME OF PARTICULATE THERAPEUTIC AND PARTICULATE DIAGNOSTIC AGENTS. | LONG DAVID M JR (US) | 1995-05-17 | — | — | EP | claimed |
| EP-0612240-A1 | METHOD FOR EXTENDING THE VASCULAR DWELL-TIME OF PARTICULATE THERAPEUTIC AND PARTICULATE DIAGNOSTIC AGENTS | Long, David M., Jr. (US) | 1994-08-31 | — | — | EP | claimed |
| US-5264220-A | Blood substitute | LONG DAVID M JR (US) | 1993-11-23 | — | — | US | claimed |
| WO-1993009762-A2 | METHOD FOR EXTENDING THE VASCULAR DWELL-TIME OF PARTICULATE THERAPEUTIC AND PARTICULATE DIAGNOSTIC AGENTS | LONG DAVID M JR (US) | 1993-05-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375539-A1 | COMPOSITIONS OF DISPERSED SYSTEMS FOR BIOMEDICAL APPLICATIONS, PROCESS FOR THEIR PREPARATION AND USES THEREOF | TLR3, MSR1, DCLRE1B | LMNA 2783/4885THRB 4078/4885CA2 2156/4885 |
| US-20070293696-A1 | ONE-STEP CATALYTIC PROCESS FOR THE SYNTHESIS OF ISOCYANATES | ADH1C, IDH2, CYP4F2 | LMNA 1814/4885THRB 3850/4885CA2 90/4885 |
| US-20260124305-A1 | TOPICAL OPHTHALMOLOGICAL COMPOSITIONS | CHRM5, FFAR3, CHRM2 | LMNA 2553/4885THRB 53/4885CA2 2160/4885 |
| US-20260130896-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | CHRM5, CHRM3, CHRM2 | LMNA 2401/4885THRB 223/4885CA2 1000/4885 |
| US-20260144875-A1 | COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS | STRA6, RBP4, F12 | LMNA 3320/4885THRB 305/4885CA2 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.